文献速递心力衰竭与心肌病

心力衰竭患者液体限制:一项系统综述

Fluid restriction in patients with heart failure: a systematic review.
PubMed 文献 · Heart · 2026-08-12

该系统综述检索截至2025年5月1日的随机对照试验,纳入4项RCT共682例心衰患者,比较液体限制与宽松/不限制摄入。由于异质性高未行荟萃分析。无证据表明液体限制影响死亡率或心衰住院,但口渴痛苦增加,当前证据不支持常规液体限制。

要点

  • 4项RCT共682例心衰患者,仅1项低偏倚风险,异质性高未行荟萃分析。
  • 无证据表明液体限制影响死亡率或心衰住院,生活质量结果矛盾。
  • 液体限制与更多口渴痛苦相关,提示潜在危害信号。

核心结论

  • 当前证据不支持对心衰患者常规使用液体限制。
  • 液体限制未显示对死亡率或心衰住院有益,但口渴痛苦增加提示潜在危害。

研究设计与样本

  • 系统综述检索CINAHL、EMBASE、PubMed和Cochrane Library截至2025年5月1日。
  • 纳入成人心衰患者随机对照试验,比较液体限制与宽松/不限制摄入、较少限制或常规护理。
  • 共纳入4项RCT,682例住院、近期出院和稳定门诊患者,每项试验46至504例。
  • 仅1项研究低偏倚风险,因异质性高未行荟萃分析。

主要发现

  • 4项试验均未发现死亡率或心衰住院的显著差异。
  • 生活质量结果矛盾,总体无明确获益,但液体限制导致更多口渴痛苦。
  • NYHA分级或(NT-pro)BNP未见显著差异。

临床怎么用

  • 不建议对心衰患者常规处方液体限制。
  • 若考虑液体限制,需权衡口渴痛苦等潜在危害。

局限性

  • 相关研究稀少,多数研究高偏倚风险。
  • 研究把握度不足,因异质性高未行荟萃分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fluid restriction is a commonly prescribed non-pharmacological intervention in the management of heart failure (HF). However, data on its efficacy and safety are scarce. Recent randomised clinical trial (RCT) data prompt reassessment of the available evidence. METHODS: CINAHL, EMBASE, PubMed and the Cochrane Library were searched up to 1 May 2025. RCTs were included if adults with HF were randomised to fluid restriction in comparison to a liberal or unrestricted intake, less strict restriction or usual care. Outcomes of interest were mortality, HF hospitalisation, quality of life (QoL), thirst distress, New York Heart Association (NYHA) class and N-terminal pro-Brain Natriuretic Peptide (CRD42022292319). No meta-analysis was performed due to high heterogeneity of the included trials. RESULTS: In total, four RCTs were included, comprising 682 randomised inpatient, recently discharged and stable outpatient patients (ranging from 46 to 504 patients per trial). Only one study had a low risk of bias. None of the four trials found a significant difference in mortality or HF hospitalisations. For QoL, the results are contradictory, but overall, there is no clear benefit for fluid restriction, but it resulted in more thirst distress. No significant differences in NYHA class or (NT-pro)BNP were observed. CONCLUSION: Studies on fluid restriction in patients with HF are scarce, and most of the available studies are at high risk of bias. Although power is lacking, there is no evidence indicating that fluid restriction affects mortality or HF hospitalisations, but there is a signal of harm in terms of thirst distress. Taken together, the current evidence does not support the routine use of fluid restriction in patients with HF.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Herrmann, van Berlo, Brunner-La Rocca, et al. Fluid restriction in patients with heart failure: a systematic review. Heart. 2026. PMID: 41529956. doi:10.1136/heartjnl-2025-326784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。